BeOne Medicines Insider Sale 13,659 ADS on 10/08/2025

Rhea-AI Filing Summary

BeOne Medicines Ltd. (BEIGF) filed a Form 144 notice reporting a proposed sale of 13,659 ADS through Morgan Stanley Smith Barney LLC on 10/08/2025, with an aggregate market value of $4,666,187.58 and 54,564,278 ADS outstanding. The filing shows the securities were acquired partly by exercise of stock options on 10/08/2025 (12,547 ADS, cash payment) and partly from restricted stock units on 07/29/2025 (1,112 ADS). The filer also disclosed three sales in the prior three months under Rule 10b5-1 and an individual sale: 09/10/2025 (10,006 ADS, $3,257,289.02), 08/13/2025 (9,342 ADS, $2,805,905.17), and 07/30/2025 (920 ADS, $280,232.74). The filer attests there is no undisclosed material adverse information and references potential reliance on a Rule 10b5-1 plan.

Positive

• Disclosure of acquisition details including dates, transaction types, and payment methods provides transparency
• Prior 10b5-1 sales disclosed (19,348 ADS across three transactions) showing structured selling history

Negative

• No explicit Rule 10b5-1 plan adoption date is provided in the visible remarks, limiting verification of safe-harbor protection
• Planned sale represents a meaningful block (13,659 ADS / 54,564,278 outstanding) that could exert selling pressure on the market for the ADS

Insights

Corporate Insider Transactions Analyst

Insider plans to sell newly exercised and RSU shares totaling 13,659 ADS on 10/08/2025.

The filing shows 12,547 ADS were acquired by option exercise and 1,112 ADS via restricted stock units, with the sale routed through Morgan Stanley Smith Barney LLC. The disclosed recent 10b5-1 sales totaling 19,348 ADS across July–September indicate an ongoing, structured disposition program.

Key dependencies are the stated adoption date of any 10b5-1 plan (not listed) and market execution on 10/08/2025. Investors should note the aggregate market value of the proposed sale is $4,666,187.58, which is traceable to the number of ADS and the disclosed recent gross proceeds.

Securities Compliance Specialist

Filing aligns with Rule 144 disclosure requirements and references possible Rule 10b5-1 reliance.

The notice includes acquisition dates, nature of acquisition, payment method, prior 10b5-1 sales and a signature attestation about material information. The absence of an explicit plan adoption date in the visible remarks means reliance on a 10b5-1 plan cannot be confirmed from the text provided.

Compliance risk hinges on whether a written trading plan exists and its adoption date; if relied upon, that date should be disclosed to validate the safe-harbor timing relative to the planned sale on 10/08/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13659	4666187.58	54564278	10/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	10/08/2025	Exercise of Stock Options	Issuer			12547	10/08/2025	Cash
ADS	07/29/2025	Restricted Stock Units	Issuer			1112	07/29/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	ADS	09/10/2025	10006	3257289.02
10b5-1 Sales for CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	ADS	08/13/2025	9342	2805905.17
CHAN LEE Aeschengraben 27, 21st Floor Basel V8 4051	ADS	07/30/2025	920	280232.74

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being sold in the Form 144 filed for BEIGF?

The filing reports a proposed sale of 13,659 ADS with an aggregate market value of $4,666,187.58 through Morgan Stanley Smith Barney LLC on 10/08/2025.

How were the ADS being sold acquired according to the filing?

The filing shows 12,547 ADS were acquired by exercise of stock options on 10/08/2025 (paid in cash) and 1,112 ADS were received from restricted stock units on 07/29/2025.

Has the filer sold any ADS recently under a 10b5-1 plan?

Yes. The filing discloses three recent sales: 09/10/2025 (10,006 ADS, $3,257,289.02), 08/13/2025 (9,342 ADS, $2,805,905.17), and 07/30/2025 (920 ADS, $280,232.74), identified as 10b5-1 sales for Chan Lee.

Does the filing confirm reliance on a Rule 10b5-1 trading plan?

The notice references possible reliance on a Rule 10b5-1 plan but does not provide an explicit plan adoption date in the visible remarks, so reliance cannot be fully confirmed from this text alone.

What attestation does the filer make in the Form 144?

The filer attests by signing that they do not know any material adverse information about the issuer that has not been publicly disclosed.